3 participants
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2014-05-07
- Start Date:
- 2008-10-31
- Completion:
- 2009-02-28
Conditions
- Multiple Sclerosis
Interventions
- DRUG